Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: PawPr who wrote (686)	5/28/1998 8:07:00 PM
From: David S.	Read Replies (1) \| Respond to of 965

Without digressing too much on the Prosorba column and CYPB, it may be just a matter of timing that stock correctly. As it relates to CNTO and the serious side effect profile of today's drug of interest and others that treat RA - if I were a patient with serious RA, would I choose a treatment that had no side effects, or a drug therapy that had side effects that are as serious and in some cases, more serious the disease itself? I do not suggest that the Prosorba column will displace every drug on the market and in development for RA - far from it. However, it is clear that Prosorba and RA drugs in development will together blow away what Centocor has for RA in addition to what's currently on the market - which is good for RA patients.